Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
23.61
-1.29 (-5.18%)
Jun 16, 2025, 4:00 PM - Market closed
Janux Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Janux Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $94.29, which forecasts a 299.36% increase in the stock price over the next year. The lowest target is $41 and the highest is $200.
Price Target: $94.29 (+299.36%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Janux Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 3 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 10 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +196.48% | Mar 3, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $62 → $41 | Hold | Maintains | $62 → $41 | +73.66% | Feb 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $200 | Buy | Reiterates | $200 | +747.10% | Dec 11, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $42 → $62 | Hold | Maintains | $42 → $62 | +162.60% | Dec 4, 2024 |
| Stifel | Stifel | Strong Buy Maintains $70 → $115 | Strong Buy | Maintains | $70 → $115 | +387.08% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
1.02M
from 10.59M
Decreased by -90.37%
Revenue Next Year
8.01M
from 1.02M
Increased by 685.39%
EPS This Year
-2.04
from -1.28
EPS Next Year
-2.63
from -2.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.2M | 56.5M | 35.3M | ||
| Avg | 1.0M | 8.0M | 7.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -60.3% | 5,441.4% | 340.9% | ||
| Avg | -90.4% | 685.4% | -7.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.50 | -1.42 | -1.89 | ||
| Avg | -2.04 | -2.63 | -3.44 | ||
| Low | -3.25 | -4.66 | -5.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.